Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy

• Published in: Clinical drug investigation 2007-01, Vol.27 (5), p.333-337
• Main Authors: González, Carlos A, Rubio-Guerra, Alberto F, Pavía, Abel, Redding, Francisco J, Cervantes, José L, Zacarías, José L, Yza, Rubén, Carranza, Jaime, Fernández, Pedro, Morales, Enrique, Robles, Francisco J, Leyva, José L, Rodríguez, Leticia
• Format: Article
• Language: English
• Subjects: Anticholesteremic Agents - therapeutic use; Azetidines - therapeutic use; Cholesterol, LDL - blood; Drug Therapy, Combination; Dyslipidemias - blood; Dyslipidemias - drug therapy; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Male; Middle Aged; Treatment Outcome
• ISSN: 1173-2563
• DOI: 10.2165/00044011-200727050-00004

Elevated serum low-density lipoprotein cholesterol (LDL-C) is a major cardiovascular risk factor. This study aimed to determine the efficacy and safety of co-administration of the cholesterol absorption inhibitor ezetimibe with an HMG-CoA reductase inhibitor (statin) in the treatment of Mexican patients with dyslipidaemia who had not attained the LDL-C treatment goal with statin monotherapy. We studied 256 patients with elevated serum LDL-C (as defined by the US National Cholesterol Education Program Adult Treatment Panel III guidelines) despite statin therapy. All patients had lipid profiles performed at baseline and after 6-8 weeks of treatment with statin therapy plus ezetimibe 10 mg/day for 6-8 weeks. Addition of ezetimibe to statin treatment reduced mean serum LDL-C levels significantly (from 160 +/- 42.8 to 100 +/- 36 mg/dL; p